With a diverse drug portfolio and a robust pipeline of ... of therapies across multiple clinical areas including oncology, ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The 51-year-old from Northamptonshire, in central England, was diagnosed with incurable cancer in 2015. After he stopped ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug ... over year to €92 million due to generic competition. In Oncology, Sarclisa sales rose 23.7% year over year to €114 million ...

Sanofi already has an exclusive licence with OranoMed and its US partner RadioMedix to develop a drug using radioactive lead isotopes for neuroendocrine tumours, a rare cancer affecting cells that ...

Access to innovation is proving increasingly difficult for UK cancer patients. Unpicking the policy barriers is important for ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

New Delhi: Reviewing the Phase III clinical trial protocol of the GZ402671 (Venglustat) presented by the pharma major Sanofi, ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

French unions have called on workers at Sanofi to strike starting on Thursday ... sufficiency in the field of medical equipment and drugs. They also fear Sanofi’s decision to sell a controlling ...